Celldex Therapeutics (NASDAQ: CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $22.000 thousand which missed the analyst consensus estimate of $954.444 thousand by 97.69 percent. This is a 96.99 percent decrease over sales of $730.000 thousand the same period last year.